Ország: Svédország
Nyelv: svéd
Forrás: Läkemedelsverket (Medical Products Agency)
ciprofloxacinhydroklorid (monohydrat)
Medical Drug Supplies Ltd
J01MA02
ciprofloxacin hydrochloride (monohydrate)
250 mg
Filmdragerad tablett
ciprofloxacinhydroklorid (monohydrat) 291,1 mg Aktiv substans; laktosmonohydrat Hjälpämne
Apotek
Receptbelagt
Ciprofloxacin
Förpacknings: Blister, 20 tabletter
Avregistrerad
2015-06-17
Page 1 of 11 PACKAGE LEAFLET: INFORMATION FOR THE USER CIPROFLOXACIN ACCORD 250 MG FILM-COATED TABLETS CIPROFLOXACIN ACCORD 500 MG FILM-COATED TABLETS CIPROFLOXACIN ACCORD 750 MG FILM-COATED TABLETS ciprofloxacin READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist or nurse. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Ciprofloxacin Accord is and what it is used for 2. What you need to know before you take Ciprofloxacin Accord 3. How to take Ciprofloxacin Accord 4. Possible side effects 5. How to store Ciprofloxacin Accord 6. Contents of the pack and other information 1. WHAT CIPROFLOXACIN ACCORD IS AND WHAT IT IS USED FOR Ciprofloxacin Accord contains the active substance ciprofloxacin. Ciprofloxacin is an antibiotic belonging to the fluoroquinolone family. Ciprofloxacin works by killing bacteria that cause infections. It only works with specific strains of bacteria. ADULTS Ciprofloxacin Accord is used in adults to treat the following bacterial infections: • respiratory tract infections • long lasting or recurring ear or sinus infections • urinary tract infections • genital tract infections in men and women • gastro-intestinal tract infections and intra-abdominal infections • skin and soft tissue infections • bone and joint infections • to prevent infections due to the bacterium _Neisseria meningitidis _ • anthrax inhalation exposure Ciprofloxacin may be used in the management of patients with low white blood cell counts (neutropenia) who have a fever that is suspected to be due to a bacterial infection. If yo Olvassa el a teljes dokumentumot
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Ciprofloxacin Accord 250 mg film-coated tablets Ciprofloxacin Accord 500 mg film-coated tablets Ciprofloxacin Accord 750 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 250 MG: Each film-coated tablet contains ciprofloxacin hydrochloride equivalent to 250 mg ciprofloxacin. Excipient(s) with known effect: Contain 2.7 mg of Lactose monohydrate For the full list of excipients, see section 6.1. 500 MG: Each film-coated tablet contains ciprofloxacin hydrochloride equivalent to 500 mg ciprofloxacin. Excipient(s) with known effect: Contain 5.4 mg of Lactose monohydrate For the full list of excipients, see section 6.1. 750 MG: Each film-coated tablet contains ciprofloxacin hydrochloride equivalent to 750 mg Ciprofloxacin. Excipient(s) with known effect: Contain 8.2 mg of Lactose monohydrate For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet 250 mg: White to off-white, round, approximately 10 mm in diameter biconvex film coated tablet with inscription ‘AM’ on one side and plain on other side. 500 mg: White to off-white, approximately 17 mm in length, 7.5 mm in width, capsule shape, biconvex with beveled edge, film coated tablet with inscription ‘CI’ on one side and plain on other side. 750 mg: White to off-white, approximately 19 mm in length, 10 mm in width, capsule shape, biconvex with beveled edge, film coated tablet with inscription ‘CJ’ on one side and plain on other side. 4. CLINICAL PARTICULARS 4.1. THERAPEUTIC INDICATIONS Ciprofloxacin are indicated for the treatment of the following infections (see sections 4.4 and 5.1). Special attention should be paid to available information on resistance to ciprofloxacin before commencing therapy. Consideration should be given to official guidance on the appropriate use of antibacterial agents. ADULTS: • Lower respiratory tract infections due to Gram-negative bacteria - exacerbation of chronic obstructive pulmonary disease. In exacerbat Olvassa el a teljes dokumentumot